Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Scrip Awards
Partnered Content
Scrip Asia 100
Report Store
Ask The Analyst
PItCH
PDF Library
RSS Feeds
Subscribe
Advertise
UsernamePublicRestriction

Shanghai Fosun Pharmaceutical Group Co. Ltd.

Division of Fosun International Ltd.
www.fosunpharma.com/en

Latest From Shanghai Fosun Pharmaceutical Group Co. Ltd.

Bookmark
  • Analysis

Mylan Gets Expert Panel Go-Ahead For Pretomanid In India

By Anju Ghangurde

Tuberculosis drug pretomanid gets endorsement, with Phase III trial waiver, from a key expert panel that advises India's drugs regulator, but roll out plan needs to be defined under the country’s national TB program, say health activists.

Research & Development Clinical Trials
Bookmark
  • News

Asia Deal Watch: Fujifilm Affiliate Out-Licenses Antifungal Candidate To Canada’s Appili

By Ian Haydock, Joseph Haas, Vibha Ravi and Jung Won Shin

Novel antifungal T-2307, discovered by FUJIFILM Toyama, works by selectively disrupting mitochondrial function. Excelra and Maruho team up to repurpose existing drugs.

Asia Pacific Deals
Bookmark
  • Analysis

Global Top Three Trade Places As Going Gets Tough, Especially In The US

By Aidan Fry

Mylan has moved up to become the world’s leading generics, biosimilars and OTC player, according to Generics Bulletin’s newly compiled global rankings. Sandoz has surpassed troubled Teva into second spot, but is set to surrender that position once it sells its US solid-dose and dermatology business to India’s Aurobindo, which has already moved into the global top 10.

Sales & Earnings Companies
Bookmark
  • News

International Demand For Robotic Surgery Drives Intuitive Surgical’s Revenues Up 21% in Q2

By Reed Miller

Intuitive Surgical reported on 18 July that worldwide da Vinci procedures were up about 17% in the second quarter of 2019 compared to the same period of 2018. While the US still accounts for the majority of Intuitive’s revenue, procedure volume outside the US is growing faster, especially in Asia.

Companies Sales & Earnings
See All

Company Information

UsernamePublicRestriction

Register

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By